Document resource
Background and Importance Patient safety is a critical concern during hospital discharge. For patients undergoing Bone Marrow Transplantation (BMT), therapeutic complexity highlights Prescription-Related Medication Problems (PRMPs) as markers of vulnerability in the transition of care. The pharmacist acts as a crucial barrier for preventing failures, contributing to the safety and continuity of treatment.Aim and Objectives To identify and classify prescription PRMPs at hospital discharge for BMT patients, assessing the impact of pharmaceutical interventions on safety and continuity of treatment.Material and Methods This was a retrospective, descriptive, real-world, observational study conducted at a large public, university-affiliated, tertiary hospital. Discharge prescriptions for patients over 18 years old between March and December 2023, related to BMT or post-transplant complications, were included. PRMPs were identified, classified according to standardised categories (necessity, effectiveness, and safety), and quantified by frequency and type of pharmaceutical intervention performed.Results A total of 97 discharges were evaluated, of which 84 (86.6%) included pharmaceutical counselling. The mean age was 45.5 ± 13.2 years, with 57.1% male (n=48). Among the discharges, 55 (65.5%) were autologous transplants, 27 (32.1%) were allogeneic, and 2 (2.4%) were CAR-T Cell therapy.PRMPs were identified in 42.9% (n=36) of the prescriptions, with 100% of pharmaceutical interventions accepted by the medical team. In total, 44 PRMPs were classified as: 90.9% (n=40) related to necessity, 6.8% (n=3) to effectiveness, and 2.3% (n=1) to safety. The most frequent causes included absence of necessary medication therapy during the transition of care (63.6%), inadequate substitution of medicines (21.2%), and lack of antifungal validation by the hospital infection control committee (18.2%).Conclusion and Relevance PRMPs at hospital discharge for post-BMT patients highlight significant vulnerabilities in care continuity. The presence of the clinical pharmacist during medication reconciliation and discharge counselling reduces risks, increases adherence, and strengthens safety during the hospital-to-home transition. The study reinforces the need for systematic integration of pharmaceutical assessment into the hospital discharge process, especially in high-complexity populations like onco-haematology.Conflict of Interest No conflict of interest